PT3310389T - Composições tópicos compreendendo um corticosteroide e um retinoide para o tratamento da psoríase - Google Patents

Composições tópicos compreendendo um corticosteroide e um retinoide para o tratamento da psoríase

Info

Publication number
PT3310389T
PT3310389T PT167294701T PT16729470T PT3310389T PT 3310389 T PT3310389 T PT 3310389T PT 167294701 T PT167294701 T PT 167294701T PT 16729470 T PT16729470 T PT 16729470T PT 3310389 T PT3310389 T PT 3310389T
Authority
PT
Portugal
Prior art keywords
retinoid
corticosteroid
topical compositions
treating psoriasis
psoriasis
Prior art date
Application number
PT167294701T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Valeant Pharmaceuticals North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3310389(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Pharmaceuticals North America filed Critical Valeant Pharmaceuticals North America
Publication of PT3310389T publication Critical patent/PT3310389T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT167294701T 2015-06-18 2016-06-06 Composições tópicos compreendendo um corticosteroide e um retinoide para o tratamento da psoríase PT3310389T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562181481P 2015-06-18 2015-06-18

Publications (1)

Publication Number Publication Date
PT3310389T true PT3310389T (pt) 2020-11-11

Family

ID=56131662

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167294701T PT3310389T (pt) 2015-06-18 2016-06-06 Composições tópicos compreendendo um corticosteroide e um retinoide para o tratamento da psoríase

Country Status (20)

Country Link
US (7) US10251895B2 (https=)
EP (1) EP3310389B1 (https=)
JP (1) JP6997624B2 (https=)
KR (2) KR102643849B1 (https=)
CN (1) CN108282998B (https=)
AU (1) AU2016279801B2 (https=)
BR (1) BR112017027332B1 (https=)
CA (1) CA2988577A1 (https=)
CY (1) CY1123354T1 (https=)
DK (1) DK3310389T3 (https=)
ES (1) ES2812451T3 (https=)
HR (1) HRP20201250T1 (https=)
HU (1) HUE050603T2 (https=)
LT (1) LT3310389T (https=)
MX (1) MX377544B (https=)
PL (1) PL3310389T3 (https=)
PT (1) PT3310389T (https=)
RS (1) RS60672B1 (https=)
SI (1) SI3310389T1 (https=)
WO (1) WO2016205001A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
CN108282998B (zh) * 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
MX2018000421A (es) * 2015-07-13 2018-05-17 Dr Reddy´S Laboratories Ltd Composiciones de retinoides topicos.
WO2018209262A1 (en) * 2017-05-12 2018-11-15 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
PL3641728T3 (pl) * 2017-06-23 2021-09-20 Laboratorios Salvat, S.A. Kompozycja klobetazolu w postaci nanoemulsji typu olej w wodzie
US11364198B2 (en) * 2018-04-05 2022-06-21 Bausch Health Ireland Limited Polymeric emulsion delivery systems
US10653656B2 (en) * 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
EP3937905A4 (en) * 2019-03-14 2022-12-28 Crescita Therapeutics Inc. RINSING COMPOSITIONS AND THEIR USES FOR THE ADMINISTRATION OF ACTIVE AGENTS
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
CN113116891B (zh) * 2019-12-30 2024-07-16 重庆华邦制药有限公司 一种乳膏及其制备方法
KR102451304B1 (ko) 2020-09-14 2022-10-07 한국과학기술연구원 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102461001B1 (ko) 2020-09-14 2022-11-01 한국과학기술연구원 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102769642B1 (ko) 2021-09-17 2025-02-20 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102692893B1 (ko) 2021-09-17 2024-08-08 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
CN113975249B (zh) * 2021-10-14 2023-01-03 中山大学·深圳 Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用
CN113712918A (zh) * 2021-10-28 2021-11-30 济南纽华医药科技有限公司 一种阿普斯特微乳及其制备方法
WO2024141639A1 (en) * 2022-12-31 2024-07-04 Bausch Health Ireland Limited Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a
WO2024201481A1 (en) * 2023-03-29 2024-10-03 Scires Technologies Private Limited Anti-psoriasis topical formulation containing combination drugs and method of preparation thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75903A1 (https=) 1976-09-29 1978-05-16
NL7105591A (en) 1971-04-24 1972-10-26 Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4-
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5850964B2 (ja) 1978-03-07 1983-11-14 東興薬品工業株式会社 ステロイド含有クリ−ム製剤およびその製造方法
US4233295A (en) 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
US4299828A (en) 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
AU5794680A (en) 1979-05-31 1980-12-04 E.R. Squibb & Sons, Inc. Corticosteroid stick formulations
CH649923A5 (de) 1980-10-06 1985-06-28 Glaxo Group Ltd Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide.
JPS58225009A (ja) 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
DE3225848A1 (de) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
CA1303991C (en) 1986-03-31 1992-06-23 Chung H. Cheng Composition and method for delivering a steroid active ingredient
US5019569A (en) 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
JPH0676328B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
JPH0676327B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
JPH07116026B2 (ja) 1987-07-07 1995-12-13 株式会社資生堂 ジクロフェナックナトリウム含有乳化外用剤
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
KR0168436B1 (ko) 1990-03-02 1999-01-15 후쿠하라 요시하루 비스테로이드계 소염진통제를 함유하는 수중유형 유화 조성물
TW218849B (https=) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
CA2282682C (en) * 1997-02-20 2008-08-19 Allergan Sales, Inc. Tazarotene and corticosteroid treatment for psoriasis
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
GB9823036D0 (en) 1998-10-22 1998-12-16 Glaxo Group Ltd Fluticasone lotion having improved vasoconstrictor activity
AU2877800A (en) * 1999-02-12 2000-08-29 Susan Bershad Short contact treatment of psoriasis with topical retinoids
US6730308B1 (en) * 1999-03-08 2004-05-04 Allergan, Inc. Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
BRPI0114927B8 (pt) * 2000-10-27 2021-05-25 Leo Pharma As composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
CN1210034C (zh) * 2002-12-06 2005-07-13 重庆华邦制药股份有限公司 治疗银屑病的药物组合物
AU2003302305A1 (en) 2002-12-31 2004-07-22 Sachin S Bhagwat Benzoquinolizine-2-carboxylic acid-containing compositions
JP2004359585A (ja) 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
CN1210035C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗银屑病的复方外用药物
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
JPWO2006098353A1 (ja) 2005-03-15 2008-08-28 協和醗酵工業株式会社 外用剤
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
EP1968541A2 (en) 2005-12-14 2008-09-17 Zars, Inc. Compositions and methods for dermal delivery of drugs
PT2494959E (pt) 2006-07-05 2015-02-20 Foamix Pharmaceuticals Ltd Veículo formador de espuma de ácido dicarboxílico e suas composições farmacêuticas
AU2007355106A1 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
RU2470645C2 (ru) 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
WO2009084020A2 (en) 2007-10-18 2009-07-09 Glenmark Pharmaceuticals Limited Topical composition comprising halobetasol and salicylic acid
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
CN102438590B (zh) 2009-02-25 2013-07-10 施泰福研究澳大利亚有限公司 局部泡沫组合物
US20130310355A1 (en) 2009-12-15 2013-11-21 Young Pharmaceuticals, Inc. Low toxicity topical active agent delivery system
US9782341B2 (en) 2010-10-15 2017-10-10 John E. Kulesza Delivery of hydrophobic bioactive agents
WO2012061630A2 (en) * 2010-11-04 2012-05-10 442 Ventures, Llc Composition and method for treating skin conditions
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US9034926B2 (en) * 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
TW201311295A (zh) 2011-06-03 2013-03-16 Allergan Inc 對皮脂腺之類視色素化合物之目標遞送
SG11201403762PA (en) * 2012-01-09 2014-07-30 Almirall Sa Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
CN104288157B (zh) * 2013-01-29 2018-04-13 江苏知原药业有限公司 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法
CA2925676A1 (en) * 2013-09-25 2015-04-02 Sun Pharmaceutical Industries Limited Topical spray composition of halobetasol
US20190133943A1 (en) 2015-06-18 2019-05-09 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases
CN108282998B (zh) * 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
WO2018209262A1 (en) 2017-05-12 2018-11-15 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases

Also Published As

Publication number Publication date
MX2017015990A (es) 2018-11-09
KR20180053292A (ko) 2018-05-21
US11679116B2 (en) 2023-06-20
HRP20201250T1 (hr) 2020-11-13
RS60672B1 (sr) 2020-09-30
US20180177803A1 (en) 2018-06-28
US20230355640A1 (en) 2023-11-09
AU2016279801A1 (en) 2018-01-04
KR20240035898A (ko) 2024-03-18
SI3310389T1 (sl) 2020-11-30
KR102643849B1 (ko) 2024-03-07
US10251895B2 (en) 2019-04-09
BR112017027332A2 (pt) 2018-09-04
WO2016205001A1 (en) 2016-12-22
JP2018526325A (ja) 2018-09-13
MX377544B (es) 2025-03-10
US20210145847A1 (en) 2021-05-20
JP6997624B2 (ja) 2022-01-17
ES2812451T3 (es) 2021-03-17
CA2988577A1 (en) 2016-12-22
US11648256B2 (en) 2023-05-16
US10426787B2 (en) 2019-10-01
US20230086282A1 (en) 2023-03-23
KR102779108B1 (ko) 2025-03-07
HUE050603T2 (hu) 2020-12-28
EP3310389A1 (en) 2018-04-25
AU2016279801B2 (en) 2021-09-09
PL3310389T3 (pl) 2020-11-30
CN108282998A (zh) 2018-07-13
US20160367570A1 (en) 2016-12-22
EP3310389B1 (en) 2020-07-01
LT3310389T (lt) 2020-11-10
CY1123354T1 (el) 2021-12-31
US20190231797A1 (en) 2019-08-01
BR112017027332B1 (pt) 2023-11-07
US11679115B2 (en) 2023-06-20
CN108282998B (zh) 2021-07-06
US20210330681A1 (en) 2021-10-28
DK3310389T3 (da) 2020-08-10

Similar Documents

Publication Publication Date Title
PL3310389T3 (pl) Kompozycje miejscowe zawierające kortykosteroidy i retinoidy do stosowania w leczeniu łuszczycy
ZA201800080B (en) Topical retinoid compositions
ZA201802666B (en) Devices and methods for enhancing the topical application of a benefit agent
PL3442480T3 (pl) Sposób podawania miejscowego
IL241191B (en) Local compositions and kits that include them for the treatment of local disorders
EP3133939A4 (en) Topical compositions and methods for reducing oxidative stress
ZA201606704B (en) Topical corticosteroid compositions
PL2896395T3 (pl) Preparat do miejscowego leczenia ran
EP3189074A4 (en) Compositions and methods for treating and preventing inflammation
PT3484457T (pt) Formulação tópica para promover cicatrização de feridas
EP3164139A4 (en) Topical compositions and methods for treating wounds
EP3250196A4 (en) Healing topical composition
SG11201706938XA (en) Topical formulation
PT3324938T (pt) Formulações tópicas e tratamentos
GB201517878D0 (en) A topical herbal healing formulation
EP3273951A4 (en) Compositions and methods for treating psoriasis
PL3319616T3 (pl) Kompozycje pektynowe do zapobiegania wystąpieniu i leczenia chorób zapalnych
IL272945A (en) Local preparations and methods of treatment
IL246800A0 (en) Local antifungal preparation for the treatment of nail fungus
EP3331541A4 (en) Compositions and methods for treating wounds
HUE068403T2 (hu) Új eljárás állatgyógyászati szerek helyi alkalmazására
GB201513108D0 (en) Topical composition
IL268715A (en) Preparations for the treatment of acne
PT3349722T (pt) Tratamento tópico para hirsutismo
HK1230488A1 (en) Topical antifungal composition for treating onychomycosis